Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
All the lights have turned GREEN! I'm not a big believer in charts when it comes to small non-rev bios, but I see a double bottom and a pps about ready to break above the 50 day MA. Add to that the upcoming known catalysts, and an Election outcome that is positive for us, and green is all I can see from here. Buy Buy Buy! Let's make AVXL Great Again!
I agree, in-licensing for only one indication like MS would not make sense; difficult to control the revenue as other indys are written/approved. My theory is that Biogen has seen our preliminary data on AD, and liked it. So now they want to see if we could also be helpful in their MS pipeline before making a deal for the whole compound A2-73. With the refined data analysis of Ariana and their own lab tests, they can make an informed decision about the value of our compound. They want to nail this down before CTAD, IMO.
No problem Ziggy. I thought it was odd that you predicted a down day coming after I had just read the news about Biogen. You are right to think the price could still go either way, and it's probably too soon to expect more news today. My point is, you never know when news will come, and I'd rather be all in at this level, perhaps a little jealous I can't put more in myself.
OK then! Ziggy doesn't want to be questioned. BeingReal was just making an observation. Go AVXL~BIIB
I agree, if Ziggy can buy here, why wait until tomorrow. Based on today's PR from Biogen, we could hear from Anavex tomorrow about how Biogen is moving forward with pre-clinical trials with A2-73 for MS. Filling the Gap works in both directions!
MJFF Conference I asked IR today this question..." can you confirm if any data of our work (Anavex-pre-clinical data) will be presented by anyone at the MJFF conference? "
The're reply stated that Anavex has not made an announcement for the conference.
They didn't say no, or we don't know, they said they haven't announced it. YET....IMO They also stated that events announced will be posted on their "Events Page". I informed them that "Future events are not posted there and asked if they could update the page for future planned events. We'll see...
Your conclusion is only one hypothesis:
DarkForce, as long as that's your perspective, "a cheap roll of the dice", I think you're right. Oct. options for the $5 strike were sold today for $.10 and 86 contracts were purchased; if the pps goes up a $1.00 in the next few days, those options may go up 2-3x's. But, time is not on our side. Roll 'em if you've got 'em!
I agree with IMHO's reply to your AVXL options question. I would like to emphasize his point number 4...
I agree Rising Sun
Normally I would not think the macro market conditions have a strong correlation to a startup bio like AVXL, but do you think the inclusion on the Russell 3000 could now tie us in to the type of market swing we are seeing today? Not much has been said here about the Russell 3000 except when we saw some buying...now maybe we see the downside to being linked in an index, IMO. Thoughts???
In reply to Shub and 123Tom
Interesting to watch this 200K share bid @ $3.13...If you want to buy any shares today it looks like you'll have to jump over this offer because he is buying everything available at that price, so far 17K in the first 30 mins.
No mail here, or was your question rhetorical?
We're in the "Driver's Seat" now, with the S3 filing. It's all about being ready for anything and not being a beggar at the negotiation table.
Thanks, we agree
Similar partnership news could come tomorrow for AVXL, STEM up 461% on the news. Interesting that the big move in this penny stock occurred after what the CEO said after modest phase 2 clinical trial results:
Based on the Surprisingly low volume today.. and Since you asked
Nice to see some real buying to break us out of the basement. Go AVXL!
I agree,our current health care system has many flaws. There must be open market availability of all insurance programs across state lines to create the competitive nature of an open market. My question still stands, what does having a single payer health care program in one state do to leveling the playing field between Big Pharma and new bio companies with developing pipelines like Anavex? I'm only asking because I have no idea how a single payer system changes the obstacles in the way of new drug innovation. Please elaborate regarding how the single payer system will help us and Anavex.
Xena, can you explain how the single payer system would benefit bios like Anavex and reduce the power of BP and insurance companies? TIA, in reply to
Yes, no sales, but what about news or updates from the company on their progress, more data or status of partnership discussions? Could any potential news be disclosed in their report or is it standard to release news only in PR or at a conference?
Does anyone consider the q2 report on Thursday after hours a catalyst? What is the likelihood that we will get any news that could move the pps in either direction? What is typical for start ups without sales rev? Opinions???
XenaLives mentioned Margin Call Covering the other day. Today (One week since the plunge of AVXL) is the deadline for those calls to be covered...IMO that was part of why the price has not bounced as much as it could have. (Another consequence of the manipulation) Today's bounce should hold, the bottom was found yesterday. IMHO..GREEN DAYS AHEAD!
Frrol, I always appreciate your wisdom and perspective.
Thanks bas; the trading manipulation can easily be seen here. Even before the halt of trading, you can see when the ask was put it far lower than the prior ask. The first time it happens is at 13:01:10 when the ask goes from $7.07 to $6.48. It happens several more times in the sequence, not just caused by pinned up trades waiting for trading to resume. Also, notice that the trading platform "Q" and "DEX" are involved when this happens. I'd send that whole day of trading to the sec for investigation. If you want to send me the whole chart I'd be glad to do the detail work, post it here or reply if available. Thanks to KarenCA for providing it, and TIA for anything you can do.
Our Data Is Good, the Market response was BAD. This will take time but we will see the pps go up and fill the gap as the science is understood. Keep the faith, lives are depending on us to deliver.
No Stop Loss here, holding Long and Strong. PPS has stabilized @$4.50 and remember....just as much buying as selling, one doesn't happen without the other. Good sign, expect we will see inst's buying in over the next several days/weeks.
We need to get back to the science. So far, I'm seeing good results. Can anyone with more knowledge about the study markers enlighten us?
Yes, HALTED, as I predicted! Can't wait to see what's next!
3, 2, 1, lift off!
IMO, releasing the PR mid-day could cause a halt in trading, as per regulations:
"When a company is listed on a U.S. stock exchange, including NYSE, NYSE MKT, NYSE Arca, the NASDAQ Stock Market and the BATS Exchange, it agrees to notify the listing exchange about any corporate developments that could affect trading activity in its stock—before announcing them to the public. These developments can include:
changes related to the financial health of the company;
major corporate transactions like restructurings or mergers;
significant positive or negative information about its products;
changes in key management individuals; and
legal or regulatory developments that affect the company’s ability to conduct business.
For their part, the listing U.S. stock exchanges have the authority to halt trading based on their evaluation of a given announcement. Generally, the more likely the announcement is to affect the stock price, whether positively or negatively, the more likely the exchange is to call for a trading halt pending dissemination of news by the issuer. "
We won't know until we know, but it could happen, IMO.
neiu, if you're correct, expect a halt in mid-day trading.[quoteUnder the embargo they cannot release anything until the start of the poster session][/quote]
I agree with McMagyar
That puts us right in the "Sweet Spot" as a maintenance drug.
New Patent application; A 2-73 + CBD...suggested IMHO.
Agreed Jimmy, Missling will drop that bomb between now and Monday morning; that would do the most damage to the shorts! No one can complain that they didn't have time to load up on this before the news, and the shorts, well....let me get my violin ready.
I believe the answer to your question has been glossed over by this board. During the interview, Dr. B provided a clue to his overall strategy in answering a question about Kevetrin. I believe the same strategy holds true for Brilacidin. Consider what Dr. B. said here:
"Further, we believe that it will be an anchor if we can demonstrate that the response in rodents is mirrored in treatment of patients.
To accomplish this, we are doing studies in the lab in animal models of ovarian cancer aimed at demonstrating the effect of Kevetrin TM activation of p53 to treat the disease. This strategy should enable us to further anchor the effect of Kevetrin TM in the Phase 2 trial as it relates to key biologic measures. In my opinion, many companies make a mistake by prematurely jumping to a long-term endpoint such as progression-free survival, before proof of concept is firmly established. It is a compelling story to tell if you can see the effect of a compound in an animal model replicated in human studies."
In addition, with the immune system, we know that the immune response, which includes how our system attacks a foreign element and the resulting inflammatory outcome, it makes sense to learn as much as we can about our drug in B-UP and B-OM in a cost and time efficient way. The results of these trials will clearly provide insights to how B works and confirm how to proceed. IMO.
The Aug. Options have the most risk, likewise they have the most reward, short term. As a percentage of gain vs. basis, the Aug. options will rise and fall much more quickly as they near expiry date and according to where the pps goes. If you try them, only do what you can afford to lose, and be ready to pull the trigger (close the position) before the pps tops out. Otherwise you could find it difficult to sell your options before they expire.
Thanks to you and several others on the possible outcomes of the two posters. The suspense surrounding the second poster on Wednesday makes it unlikely that we will see a decline of the pps between Sunday and Wednesday. If Wednesday surprises to the upside, we will go through the roof. Anyone long will want to wait for both presentations.